Beam Therapeutics Inc. (BEAM) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 103.29M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 103.29M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 103.29M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 103.29M | (m) | (m) |
| 2026-03-31 | 102.88M | (m) | (m) |
| 2025-09-30 | 101.47M | (m) | (m) |
| 2025-06-30 | 101.16M | (m) | (m) |
| 2025-03-31 | 100.56M | (m) | (m) |
| 2024-09-30 | 82.81M | (m) | (m) |
| 2024-06-30 | 82.42M | (m) | (m) |
| 2024-03-31 | 82.31M | (m) | (m) |
| 2023-09-30 | 81.50M | (m) | (m) |
| 2023-06-30 | 79.20M | (m) | (m) |
| 2023-03-31 | 76.22M | (m) | (m) |
| 2022-12-31 | 72.40M | (m) | (m) |
| 2022-09-30 | 70.47M | (m) | (m) |
| 2022-06-30 | 70.35M | (m) | (m) |
| 2022-03-31 | 70.27M | (m) | (m) |
| 2021-12-31 | 68.73M | (m) | (m) |
| 2021-09-30 | 68.14M | (m) | (m) |
| 2021-06-30 | 66.35M | (m) | (m) |
| 2021-03-31 | 62.58M | (m) | (m) |
| 2020-12-31 | 62.42M | (m) | (m) |
| 2020-09-30 | 57.97M | (m) | (m) |
| 2020-06-30 | 51.73M | (m) | (m) |
| 2020-03-31 | 51.49M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |